GB-115


Retrodipeptide cholecystokinin-1 (CCK-1) receptor antagonist with anxiolytic, anti-inflammatory, analgesic, and immunomodulatory activity

A synthetic retrodipeptide analogue of cholecystokinin tetrapeptide (CCK-4) designed at the Zakusov Research Institute of Pharmacology, distinguished by selective central CCK-1 receptor antagonism, non-benzodiazepine anxiolytic activity, and a favorable safety profile confirmed through Phase 3 clinical evaluation under the trade name Ranquilon.

Abstract

GB-115 (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide; CAS 678996-63-9) is a synthetic retrodipeptide analogue of the endogenous anxiogenic tetrapeptide cholecystokinin-4 (CCK-4, Trp-Met-Asp-Phe-NH2), designed and synthesized at the V.V. Zakusov Research Institute of Pharmacology (Russian Academy of Medical Sciences) using the topochemical Shemyakin-Ovchinnikov-Ivanov principle for rational peptide drug design. The biologically active conformation of GB-115 has been identified by nuclear Overhauser effect NMR spectroscopy as a type II beta-turn, with the native spatial distance between the phenyl and indolyl hydrophobic pharmacophores critical for receptor interaction. Structure-activity relationship studies demonstrated that L-tryptophan-containing derivatives produce anxiolytic effects, while D-tryptophan-containing enantiomers produce anxiogenic effects mirroring CCK-4 itself, confirming the stereospecificity of the CCK-1 receptor interaction.

Preclinical pharmacology extends beyond anxiolysis. GB-115 potentiates morphine-induced analgesia through supraspinal opioidergic mechanisms and produces independent antinociceptive activity in chemical and thermal pain models with a significant non-opioid component. Immunomodulatory activity includes stimulation of phagocytic activity of peritoneal macrophages and humoral immune response in intact mice and immunocorrecting effects in animals with secondary immunodeficiency. The compound reverses antinociceptive tolerance to morphine on sub-chronic co-administration, a property consistent with its CCK-1 receptor antagonist mechanism given the established role of cholecystokinin in opioid tolerance.

Pharmacokinetics are characterized by rapid oral absorption, low absolute bioavailability (approximately 4.65 percent in animal models), and a short elimination half-life of approximately 1.0 hour in humans. The amide bond confers greater peptidase resistance than native peptide bonds, extending plasma detection time relative to unmodified dipeptides.

Clinical evaluation has progressed through Phase 2 and Phase 3 trials. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph